Summary
Phenylethylamine (PEA) and the monoamine metabolites 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) have been measured in the cerebrospinal fluid (CSF) of nine paranoid schizophrenics before and after three weeks of neuroleptic treatment. Patients were classified according to the Research Diagnostic Criteria and rated by means of the Brief Psychiatric Rating Scale.
A significant increase was seen in HVA CSF concentrations during neuroleptic treatment (p<0.01). No influence was found on levels of PEA, 5-HIAA, and MHPG. Concentrations of both MHPG and 5-HIAA correlated positively with those of HVA. These results in combination with previous findings do not support the contention that PEA and NA metabolisms are grossly disturbed in paranoid schizophrenics whereas involvement of other neurotransmittersi.e. dopamine, seems more probable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartholini, G., Stadler, H., Gadea Ciria, M., Lloyd, K. G.: The use of the pushpull cannula to estimate the dynamics of acetylcholine and catecholamines within various brain areas. Neuropharmacol.15, 515 (1976).
Beckmann, H., Reynolds, G. P., Waldmeier, P., Lauber, J., Riederer, P., Gattaz, W. F.: Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. Arch. Psychiat. Nervenkr.232, 463–471 (1982).
Bjerkenstedt, L., Gullberg, B., Härnryd, C., Sedvall, G.: Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. Arch. Psychiat. Nervenkr.224, 107–118 (1977).
Fischer, E., Heller, B.: Phenethylamine as a neurohumoral agent in brain. Behav. Neuropsychiat.4, 8–11 (1972).
Fischer, E., Spatz, H., Saavedra, J. M., Reggiani, H., Miro, A. H., Heller, B.: Urinary elimination of phenethylamine. Biol. Psychiat.5, 139–144 (1972).
Gattaz, W. F., Waldmeier, P., Beckmann, H.: CSF monoamine metabolites in schizophrenic patients. Acta psychiat. scand.66, 350–360 (1982).
Lauber, J., Waldmeier, P.: Determination of phenylethylamine by mass fragmentography in body fluids and tissues. (In preparation.)
Overall, L. E., Gorham, D. R.: The brief psychiatric rating scale. Psychol. Rep.10, 799–812 (1962).
Potkin, S. G., Karoum, F., Chuang, L. W., Cannon-Spoor, H. E., Philips, I., Wyatt, R. J.: Phenylethylamine in paranoid chronic schizophrenia. Science206, 159 (1979).
Potkin, S. G., Weinberger, D. R., Linnoila, M., Wyatt, R. J.: Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am. J. Psychiat.140, 21–25 (1983).
Sabelli, H. C., Giardina, W. J., Mosnaim, D. A., Sabelli, N. H.: A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta physio. Pol.24, 33–40 (1973).
Schweitzer, J. W., Friedhoff, A. J., Schwartz, R.: Phenethylamine in normal urine: failure to verify high values. Biol. Psychiat.10, 277–285 (1975).
Spitzer, R. L., Endicott, J., Robins, E.: Research diagnostic criteria for selected groups of functional disorders. Biometric research. New York State Psychiatric Institute, 1975.
Wode-Helgodt, B., Fyrö, B., Gullberg, B., Sedvall, G.: Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta psychiat. scand.56, 129–142 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beckmann, H., Waldmeier, P., Lauber, J. et al. Phenylethylamine and monoamine metabolites in CSF of schizophrenics: Effects of neuroleptic treatment. J. Neural Transmission 57, 103–110 (1983). https://doi.org/10.1007/BF01250052
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01250052